We provide you with 20 years of free, institutional-grade data for CRNX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CRNX. Explore the full financial landscape of CRNX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about CRNX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Crinetics Pharmaceuticals, Inc(NASDAQ:CRNX) 
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin recept...
Website: http://www.crinetics.com
Founded: 2008
Full Time Employees: 68
Founder: R. Scott Struthers, Stephen F. Betz, Ana Kusnetzow, and Yun-Fei Zhu
CEO: R. Scott Struthers
Sector: Healthcare
Industry: Biotechnology
